Melissa Johnson, MD, program director of Lung Cancer Research at Sarah Cannon, discusses the potential of certain drug classes for lung cancer.
The DLL3-specific T cell engagers for small cell lung cancer are exciting to watch, said Melissa Johnson, MD, program director of Lung Cancer Research at Sarah Cannon.
Transcript
What clinical trial and/or treatment in the pipeline most excites you?
Antibody drug conjugates have been approved in tumor types like breast cancer. We're looking now at HER2 or HER2 directed antibody drug conjugate for HER2-mutated lung cancer. We're looking at Dato-DXd and sacituzumab govitecan trop2 directed ADCs for patients in the second line, post [chemotherapy/immunotherapy] as well as patritumab deruxtecan, which is a HER3 antibody drug conjugate for patients who have acquired resistance to osimertinib. All of these drugs have in common that they work with a mechanism that's very different from chemotherapy and immunotherapy. They bind to the target and inject the cytotoxic toxin right in to the cancer cells and leave the other cells alone. We call antibody drug conjugates "smart bombs" for our patients. And those have a lot of promise in lung cancer.
I'm also excited about bispecifics. Bispecific T cell engagers are drugs that target with 2 different antibody heads, both the tumor and T cells and bring them together. I think that's probably one mechanism of resistance to [immunoncology] that we don't think about enough. Just because we're stimulating the immune system with checkpoint inhibitors doesn't mean that the immune system knows where to go to get to the lung cancer. And so these biospecifics make a lot of sense to me because they're actually binding to the cancer and coaxing the immune system to come to it. There are bispecifics being evaluated for all solid tumors, but in particular, the DLL3-specific T cell engagers for small cell [lung cancer] are exciting to me.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More